Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Holy Basil ( L.) Flower and Fenofibrate Improve Lipid Profiles in Rats with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD): The Role of Choline Metabolism.
Plants (Basel)
December 2024
Innovative Research Unit of Epithelial Transport and Regulation (iETR), Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to choline metabolism. The present study investigated the effect of holy basil ( L.) flower water extract (OSLY) on MASLD with choline metabolism as an underlying mechanism.
View Article and Find Full Text PDFElevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease.
Signal Transduct Target Ther
March 2024
Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, China.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, and the development of non-alcoholic steatohepatitis (NASH) might cause irreversible hepatic damage. Hyperlipidemia (HLP) is the leading risk factor for NAFLD. This study aims to illuminate the causative contributor and potential mechanism of Kallistatin (KAL) mediating HLP to NAFLD.
View Article and Find Full Text PDFTherapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design.
Front Pharmacol
May 2023
Department of Gastroenterology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver diseases. In most cases, NAFLD progresses from benign steatosis to steatohepatitis (NASH), and then to cirrhosis. No treatment is currently approved for NAFLD/NASH in the clinic.
View Article and Find Full Text PDFCombinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Hepatol Commun
September 2022
Gilead Sciences, Foster City, California, USA.
Article Synopsis
- Dysregulated lipid metabolism in liver cells leads to nonalcoholic steatohepatitis (NASH), which is characterized by liver fat accumulation and related harm.
- Acetyl CoA carboxylase (ACC) inhibitors, such as firsocostat, help reduce liver fat and improve NASH symptoms but can cause increased levels of triglycerides (TG) in the blood.
- Combining ACC inhibitors with PPAR or thyroid hormone receptor agonists may reduce liver fat better while countering high blood TG levels, but these combinations don't appear to effectively reduce liver fibrosis.
Phytochemical Profile, Free Radical Scavenging and Anti-Inflammatory Properties of Root Extract: Evidence from In Vitro and In Vivo Studies.
Molecules
October 2021
Exercise and Metabolism Research Center, College of Physical Education and Health Sciences, Zhejiang Normal University, Jinhua 321004, China.
In our in vitro and in vivo studies, we used root methanolic extract (AIRME), and investigated their free radical scavenging/antioxidant and anti-inflammatory properties. Primarily, phytochemical analysis showed rich content of phenols (70.92 mg of gallic acid/g) and flavonoids (16.
View Article and Find Full Text PDF